Available:*
Library | Item Barcode | Call Number | Material Type | Item Category 1 | Status |
|---|---|---|---|---|---|
Searching... | 30000010124754 | RS380 K56 2006 | Open Access Book | Book | Searching... |
On Order
Summary
Summary
Written by internationally acclaimed experts in the economics of innovation, this volume examines how the biotechnology and pharmaceutical sector is affected by the dynamics of innovation, institutions, and public policy. It contributes both theoretically and empirically to the increasingly influential Schumpetarian framework in industrial economics, which places innovation at the centre of the analysis of competition. Both quantitative and qualitative studies are included, and this varied perspective adds to the richness of the volume's insights. The contributors explore different ideas regarding the historical evolution of technology in the sector, and how firms and industry structure have co-evolved with innovation dynamics. Important policy questions are considered regarding the future of innovation in this sector and its impact on the economy.
Table of Contents
| List of figures | p. ix |
| List of tables | p. xii |
| List of contributors | p. xiv |
| Acknowledgments | p. xvii |
| 1 Introduction | p. 1 |
| Part I Innovation and industry evolution | p. 19 |
| 2 Pharmaceutical innovation as a process of creative destruction | p. 21 |
| 3 The evolution of pharmaceutical innovation | p. 73 |
| 4 Firm and regional determinants in innovation models: evidence from biotechnology and traditional chemicals | p. 112 |
| 5 Innovation and industry evolution: a comment | p. 145 |
| Part II Firm growth and market structure | p. 161 |
| 6 Heterogeneity and firm growth in the pharmaceutical industry | p. 163 |
| 7 Growth and diversification patterns of the worldwide pharmaceutical industry | p. 208 |
| 8 Entry, market structure, and innovation in a "history-friendly" model of the evolution of the pharmaceutical industry | p. 234 |
| 9 The growth of pharmaceutical firms: a comment | p. 266 |
| Part III Policy implications | p. 275 |
| 10 The effects of research tool patents and licensing on biomedical innovation | p. 277 |
| 11 Upstream patents and public health: the case of genetic testing for breast cancer | p. 327 |
| 12 Competition, regulation, and intellectual property management in genetically modified foods: evidence from survey data | p. 346 |
| 13 Governance, policy, and industry strategies: pharmaceuticals and agro-biotechnology | p. 378 |
| 14 The dynamics of knowledge accumulation, regulation, and appropriability in the pharma-biotech sector: policy issues | p. 402 |
| Index | p. 432 |
